HF Advisory Group LLC Increases Stock Position in Elevance Health, Inc. $ELV

HF Advisory Group LLC lifted its position in shares of Elevance Health, Inc. (NYSE:ELV) by 1,797.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 152,705 shares of the company’s stock after buying an additional 144,655 shares during the quarter. Elevance Health makes up 2.0% of HF Advisory Group LLC’s holdings, making the stock its 7th largest holding. HF Advisory Group LLC owned 0.07% of Elevance Health worth $53,531,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Physician Wealth Advisors Inc. lifted its position in shares of Elevance Health by 331.6% in the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after acquiring an additional 63 shares in the last quarter. Activest Wealth Management lifted its holdings in Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 34 shares in the last quarter. Rossby Financial LCC boosted its stake in Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after purchasing an additional 44 shares during the period. Motco grew its holdings in Elevance Health by 334.8% during the 3rd quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after buying an additional 77 shares in the last quarter. Finally, True Wealth Design LLC raised its position in shares of Elevance Health by 431.8% during the third quarter. True Wealth Design LLC now owns 117 shares of the company’s stock valued at $38,000 after buying an additional 95 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Up 2.1%

ELV opened at $298.99 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54. The stock’s 50 day moving average price is $317.51 and its 200-day moving average price is $332.32. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $458.75. The stock has a market cap of $65.68 billion, a price-to-earnings ratio of 11.90, a P/E/G ratio of 1.61 and a beta of 0.49.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th were issued a $1.72 dividend. The ex-dividend date was Tuesday, March 10th. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.3%. Elevance Health’s dividend payout ratio (DPR) is currently 27.39%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ELV. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $332.00 target price on shares of Elevance Health in a research note on Thursday, January 29th. Morgan Stanley dropped their price objective on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a report on Wednesday, December 17th. Weiss Ratings cut Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, February 2nd. Leerink Partners boosted their target price on Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a research report on Thursday, January 29th. Finally, Robert W. Baird increased their price target on Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th. Twelve equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Elevance Health presently has an average rating of “Moderate Buy” and an average price target of $387.40.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.